Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Lawrence Florin"'
Autor:
Ronnie Shapira-Frommer, Robert Segal, Gal Markel, Nethanel Asher, Ayala Tamir, Hagit Harati, Ronen Stoff, Shirly Grynberg, Adam Ostrowski, Lawrence Florin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/2ac901a7449f435f9fa9ba8ed5696e81
Autor:
Steven Josephs, Robert Segal, Steve Prince, Mathew Ong, Amir Jafri, Lawrence Florin, Victoria Manax, Michael Matho, Sameera Bilgrami, Annette Marleau
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c436143e6fd817bc5b104b73074d3b38
https://doi.org/10.1136/jitc-2022-sitc2022.1089
https://doi.org/10.1136/jitc-2022-sitc2022.1089
Autor:
Piotr J. Wysocki, Piotr Tomczak, Tomasz Jankowski, Tomasz Nowikiewicz, Gal Markel, Ronnie Shapira, Gokhan Demir, Mustafa Bozkurt, Sameera Bilgrami, Annette Marleau, Adam Ostrowski, Lawrence Florin, Victoria Manax, Robert Segal
Publikováno v:
Cancer Research. 83:4426-4426
Immunicom, Inc. has developed a novel subtractive immunotherapeutic apheresis method (Immunopheresis®) to selectively remove soluble tumor necrosis factor receptors, sTNF-R1 and sTNF-R2 (sTNF-Rs) generated by tumors. sTNF-Rs block the tumoricidal ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d25b0cc9cd94327194d85251c81469a8
https://doi.org/10.1158/1538-7445.am2023-4426
https://doi.org/10.1158/1538-7445.am2023-4426
Autor:
Piotr Jan Wysocki, Adam Ostrowski, Robert Segal, Victoria Manax, Pawel Potocki, Kamil Konopka, Lukasz Kwinta, Paulina Fraczek, Maciej Lubas, Mateusz Lobacz, Lawrence Florin
Publikováno v:
Cancer Research. 82:CT179-CT179
Introduction: Tumor necrosis factor-alpha (TNFα) is a pleiotropic cytokine with known antitumor activity, produced mainly by activated immune cells. Cancer cells neutralize TNFα by shedding soluble TNF receptors 1&2 (sTNF-Rs), which act as TNFα-bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e36353f61e2be146028b641c526334cb
https://doi.org/10.1158/1538-7445.am2022-ct179
https://doi.org/10.1158/1538-7445.am2022-ct179
Autor:
Adam Ostrowski, Robert Segal, Lawrence Florin, Nina Anderson, Victoria G. Manax, Annette Marleau, Steven Josephs, Piotr Jan Wysocki, Kamil Wladyslaw Konopka, Lukasz Kwinta, Pawel Michal Potocki
Publikováno v:
Journal of Clinical Oncology. 40:e13065-e13065
e13065 Background: Although the activity of the cytokine TNF-α against diverse tumor types has been widely documented, safe and effective therapies for augmenting this pathway are lacking. An immunoadsorption device, the LW-02 Column, has been devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b984e6e2862694531a1028275b27a44
https://doi.org/10.1200/jco.2022.40.16_suppl.e13065
https://doi.org/10.1200/jco.2022.40.16_suppl.e13065
Autor:
Gal Markel, Nethanel Asher, Ayala Tamir, Shirly Grynberg, Adam Ostrowski, Hagit Harati, Ronnie Shapira-Frommer, Ronen Stoff, Robert Segal, Lawrence Florin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTNFα is a cytokine produced by immune cells and by tumor cells. The soluble forms of membrane TNF receptors 1/2 (sTNF-R1/2) act as decoy to neutralize TNFα, and are highly abundant in cancer patients. Elimination of sTNF-R1/2 may therefor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a6973c1f621e62c957513b631d84d0
https://doi.org/10.1136/jitc-2021-sitc2021.526
https://doi.org/10.1136/jitc-2021-sitc2021.526
Autor:
Piotr J. Wysocki, Paweł Potocki, Kamil Konopka, Robert Segal, Lawrence Florin, Stephen M. Prince, Adam Ostrowski, Lukasz Kwinta
Publikováno v:
Cancer Research. 81:CT135-CT135
Introduction: Tumor necrosis factor-alpha (TNFα) is a pleiotropic cytokine, with known antitumor activity, produced mainly by activated immune cells. Cancer cells can neutralize TNFα by shedding soluble TNF receptors 1&2 (sTNFRs), which act as TNF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4199bd40eeb18d587fba7628b449907f
https://doi.org/10.1158/1538-7445.am2021-ct135
https://doi.org/10.1158/1538-7445.am2021-ct135
Autor:
Stephen M. Prince, Adam Ostrowski, Piotr J. Wysocki, Lawrence Florin, Lukasz Kwinta, Paweł Potocki, Kamil Konopka, Robert Segal
Publikováno v:
Journal of Clinical Oncology. 39:e13052-e13052
e13052 Background: Tumor necrosis factor-alpha (TNFα) is a pleiotropic cytokine, with known antitumor activity, produced mainly by activated immune cells. Cancer cells neutralize TNFα by shedding soluble TNF receptors 1&2 (sTNFRs), which act as TNF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6cf7b66f8f37c353e404cd6ddca0060
https://doi.org/10.1200/jco.2021.39.15_suppl.e13052
https://doi.org/10.1200/jco.2021.39.15_suppl.e13052
Autor:
Kyle Given, Esther Huffman, Nicole Sheetz, Stephen Young, Patrick Nadolny, Joanne Benedict, Mark Travers, Lawrence Florin, Brett Wilson, Andy Lawton
Publikováno v:
Therapeutic innovationregulatory science. 48(6)
TransCelerate has developed a risk-based monitoring methodology that transforms clinical trial monitoring from a model rooted in source data verification (SDV) to a comprehensive approach leveraging cross-functional risk assessment, technology, and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d4de25801e300808fd9e429c88ed71e
https://pubmed.ncbi.nlm.nih.gov/30227471
https://pubmed.ncbi.nlm.nih.gov/30227471